866-997-4948(US-Canada Toll Free)

The 2011 ASCO (American Society of Clinical Oncology) Annual Meeting - Post Conference Review and Analysis

Published By :


Published Date : Jun 2011

Category :

Therapeutic Area

No. of Pages : 82 Pages

GlobalData, the industry analysis specialist, has released its new conference alerts, “The 2011 ASCO (American Society of Clinical Oncology) Annual Meeting - Post Conference Review and Analysis”. The conference alert is an essential source of information and analysis on the emerging therapies and new disease management techniques.


The report provides complete coverage of conference. Its scope includes -

  • Qualitative analysis of the studies and clinical trials presented at the conference and their impact on the key market dynamics and future treatment paradigm.
  • Review of pre- and post-conference KOL/analyst comments
  • Market revenue data for 2010 and forecast forward to 2017 for a specific disease area (if the conference being covered is focused on a specific disease area).
  • Review of key industry trends and events which are likely to impact and change the dynamics of the concerned disease markets in the long run.

Reasons to buy

The report will serve to facilitate your decision making in the concerned therapy areas. It will allow you to -

  • Develop business strategies by understanding the trends and developments that are driving or are expected to drive the market in the concerned disease areas.
  • Explore M&A opportunities by identifying key products and market players.
  • Develop market-entry and market expansion strategies.
  • Identify key players best positioned to take advantage of the market opportunities.
  • Make more informed business decisions from the insightful and in-depth analysis of the market and the factors influencing the same.
Table of Contents

1 Table of contents

1 Table of contents 2
1.1 List of Tables 5

2 The 2011 ASCO Annual Meeting: Post Conference Key Abstracts 6
2.1 Bone Cancer 6
2.1.1 Cixutumumab Combined with Temsirolimus in Patients with Refractory Ewings Sarcoma. 6
2.2 Breast Cancer 7
2.2.1 Bone mineral density (BMD) in participants of trial BIG 198 comparing adjuvant letrozole versus tamoxifen or their sequence. 7
2.2.2 Impact of a change of body mass index (BMI) on outcome following adjuvant endocrine therapy, chemotherapy, or trastuzumab for breast cancer. 8
2.2.3 Impact of HER2-targeted therapy on overall survival (os) in patients with HER2-positive (her2 +) metastatic breast cancer (mbc). 9
2.2.4 Population-based comparison of breast cancer screening and treatment utilization by remoteness of residence in British Columbia 10
2.2.5 The relationship between age and survival outcomes for eribulin in metastatic breast cancer 11
2.2.6 Repeat use of chemotherapy in metastatic breast cancer. 12
2.2.7 Anthracycline adherence in older patients with breast cancer (BC) 13
2.2.8 Single nucleotide polymorphisms and expression/amplification of HER2 in patients with breast cancer. 14
2.2.9 Risk of breast cancer (BC) after BRCA-mutation associated ovarian cancer (BRCA-OC): Memorial Sloan-Kettering Cancer Center (MSKCC) experience. 15
2.2.10 Ongoing clinical development of lapatinib in HER2-positive (HER2+) metastatic breast cancer (MBC): An innovative approach to recruiting patients in clinical studies 16
2.2.11 A Phase III trial of adjuvant neratinib after trastuzumab in women with early-stage HER2+ breast cancer (BC). 17
2.2.12 MARIANNE: A Phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab compared with trastuzumab in combination taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer. 18
2.2.13 EMILIA: A Phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib plus Xeloda (capecitabine) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen 18
2.2.14 HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515) 19
2.2.15 Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) 20
2.2.16 SWOG S1007: A Phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less. 21
2.2.17 A Phase III randomized trial of metformin versus placebo on recurrence and survival in early-stage breast cancer. 21
2.2.18 A Phase III, multicenter, double-blind, randomized trial of celecoxib versus placebo in primary breast cancer patients: Randomized European Celecoxib Trial (REACT). 22
2.3 Cancer Prevention and Epidemiology 23
2.3.1 The burden of cancer in Japan, the US, France, Germany, Italy, Spain, Sweden, and the UK 23
2.3.2 Prevalence of recognized bone metastases in the U.S. adult population. 24
2.4 Central Nervous System Tumors 25
2.4.1 Prognostic factors for response and survival in primary central nervous system lymphoma (PCNSL) from a randomized Phase III trial. 25
2.4.2 A randomized Phase III trial comparing standard adjuvant temozolomide with a dose-dense (dd) schedule in newly diagnosed glioblastoma. 25
2.4.3 Current status of a Phase III trial of nimotuzumab (ti-EGF-R) in newly diagnosed glioblastoma. 26
2.5 Developmental Therapeutics 27
2.5.1 Expected benefits versus actual outcomes in oncology Phase III randomized controlled trials (RCTs). 27
2.6 Gastrointestinal Cancers 28
2.6.1 Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1-98 trial. 28
2.6.2 Phase II cancer vaccination trial with multiple peptides derived from novel oncoantigens against advanced esophageal cancer 29
2.6.3 A Phase II Study of Dasatinib for Patients with Imatinib-resistant Gastrointestinal Stromal Tumor (GIST). 30
2.6.4 Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the Phase III CLASSIC trial. 31
2.6.5 A Phase III study of cetuximab plus either brivanib alaninate versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial. 32
2.6.6 Randomized Phase III Study of Gemcitabine plus S-1 versus S-1 versus Gemcitabine in Unresectable Advanced Pancreatic Cancer in Japan and Taiwan: GEST study 33
2.6.7 Exposure-response Analysis to Facilitate Phase III Dose Selection for AMG 479 in Combination with Gemcitabine to Treat Metastatic Pancreatic Cancer (mpc). 34
2.7 Genitourinary cancers 35
2.7.1 The Association of Clinical Outcome to Front-line VEGF (Vascular Endothelial Growth Factor)-targeted Therapy With Clinical Outcome to Second-line VEGF-targeted Therapy In Metastatic Renal Cell Carcinoma (mRCC) Patients 35
2.7.2 A Phase II Study of Dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in Patients with Advanced or Metastatic Renal Cell Cancer (mRCC) 36
2.7.3 A Phase I trial of combined tivozanib (AV-951) and temsirolimus therapy in patients with renal cell carcinoma (RCC). 37
2.7.4 Phase II trial of gemcitabine, carboplatin, and bevacizumab in patients with advanced/metastatic urothelial carcinoma (UC). 38
2.7.5 Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year overall survival data from a Phase II trial. 39
2.7.6 Phase II trial of linifanib in patients with advanced renal cell carcinoma (RCC): Analysis of patients receiving extended therapy. 40
2.7.7 Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). 41
2.7.8 Effect of abiraterone acetate on pain control and skeletal-related events (SRE) in patients with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study. 42
2.7.9 Identification of pre- and post-treatment markers of efficacy in patients with renal cancer treated with MVA-5T4 in a Phase III study. 43
2.7.10 SYNERGY: A randomized Phase III study comparing first-line docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC). 44
2.7.11 A randomized, controlled Phase III global trial comparing sipuleucel-T plus androgen deprivation therapy versus androgen deprivation therapy alone in men with metastatic androgen dependent (hormone sensitive) prostate cancer. 45
2.7.12 A randomized, double-blind, Phase III trial comparing ipilimumab versus placebo following radiotherapy in patients with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel. 45
2.7.13 A Phase III randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). 46
2.8 Hematological Malignancy 47
2.8.1 Decitabine for the treatment of (AML): Memorial Sloan-Kettering Cancer Center experience. 47
2.8.2 The effect of elotuzumab on natural killer (NK) cell function against multiple myeloma (MM). 47
2.8.3 Clofarabine with cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the Phase III CLASSIC 1 trial 48
2.8.4 Sequential azacitidine and lenalidomide in elderly AML: completed results of the Phase I study. 49
2.8.5 Bosutinib (BOS) as a third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib and dasatinib or nilotinib. 50
2.8.6 Lenalidomide following rituximab and fludarabine in untreated Chronic lymphocytic leukemia (CLL). 51
2.8.7 Adaptive design of VALOR, a Phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory (AML). 52
2.8.8 PANORAMA1: A randomized, double-blind, placebo controlled Phase III study of panobinostat in combination with bortezomib (BTZ), and dexamethasone in patients with relapsed multiple myeloma(MM) 52
2.8.9 RESPONSE: A randomized, open label, Phase III study of INC424 in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU). 53
2.8.10 A randomized Phase III study of elacytarabine versus limited investigators choice in patients with refractory AML. 54
2.9 Hepatocellular carcinoma 55
2.9.1 Phase III Trial of Sunitinib Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) 55
2.10 Lung Cancer 56
2.10.1 Randomized Phase III trial of amrubicin versus topotecan as second- line treatment for small cell lung cancer (SCLC). 56
2.10.2 A Randomized, Double-Blind Phase III Study Of Icotinib Versus Gefitinib In Patients With Advanced Non-Small Cell Lung Cancer (Nsclc) Previously Treated With Chemotherapy (Icogen) 57
2.10.3 Effect of early palliative care on chemotherapy utilization and end-of-life care in patients with metastatic non-small cell lung cancer (NSCLC). 58
2.10.4 PROSE: Randomized proteomic stratified Phase III study of second line erlotinib versus chemotherapy in patients with inoperable nonsmall cell lung cancer (NSCLC). 59
2.10.5 Randomized Phase III trial of gemcitabine/carboplatin with or without iniparib (BSI-201) in patients with previously untreated stage IV squamous non-small cell lung cancer (NSCLC). 60
2.10.6 SCAT trial: Phase III Spanish customized adjuvant treatment according BRCA1 mRNA levels in stage II-IIIA non-small cell lung cancer. 60
2.10.7 Study ESOGIA-GFPC 08-02: Phase III, randomized, multicenter trial involving subjects over age 70 with stage IV non-small cell lung cancer and comparing a classical strategy of treatment allocation (dual-agent therapy based on carboplatin or monotherapy with docetaxel alone), based on performance status (PS) and age, with an optimized strategy allocating the same treatments according to a simplified geriatric screening scale, plus a more thorough geriatric evaluation if necessary. 61
2.10.8 A Phase II randomized trial of carboplatin, paclitaxel and bevacizumab with or without IMC-A12 (cixutumumab) in patients with advanced nonsquamous, non-small cell lung cancer (NSCLC). 62
2.10.9 A Phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC). 63
2.10.10 A randomized Phase III study of maintenance therapy with bevacizumab, pemetrexed,, or a combination of bevacizumab and pemetrexed following carboplatin, paclitaxel and bevacizumab for advanced nonsquamous non-small cell lung cancer NSCLC: ECOG trial 63
2.11 Malignant Mesothelioma 64
2.11.1 A multicenter, randomized Phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy. 64
2.12 Neuroendocrine Tumors 65
2.12.1 Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glucagon levels in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III RADIANT-3 study results. 65
2.12.2 PAZONET: A Phase II trial of pazopanib in patients with metastatic neuroendocrine tumors (NETs) who may have previously received antiangiogenic or mammalian target of rapamycin (m-TOR) treatment 66
2.13 Skin Cancer 67
2.13.1 Pharmacodynamic and predictive markers of ipilimumab on melanoma patients T cells 67
2.13.2 Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor GSK2118436 (GSK436). 68
2.13.3 Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine in patients with V600EBRAF-mutated melanoma 69
2.13.4 DERMA Phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3-positive resected stage III melanoma. 70
2.14 Solid Tumors 71
2.14.1 Eribulin dosing in patients with advanced solid tumors and hepatic impairment. 71
2.14.2 Phase I trial assessing safety and pharmacokinetics of afatinib (BIBW 2992) with intravenous weekly vinorelbine in advanced solid tumors. 72
2.14.3 AIDS malignancy consortium (AMC) study 061: A phase I/PK study of sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors. 73
2.15 Others 74
2.15.1 Meta-analysis of the pharmacokinetic variability of liposomal anticancer agents compared with nonliposomal anticancer agents. 74
2.15.2 Identification of barriers to clinical trials: The impact of education level. 75
2.15.3 Impact of out-of-pocket expenses on cancer care. 76
2.15.4 A Phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013 77
2.15.5 An evaluation of PI3K pathway activation on the efficacy of both trastuzumab and lapatinib. 78
2.16 Abbreviations 79
2.17 Disclaimer 82

List of Table

Table 1: Results of BIG-1-98 trial 8
Table 2: Preliminary results 9
Table 3: Efficacy Results of EMBRACE Trial Study 12
Table 4: Efficacy results of repeat use of chemotherapy in metastatic breast cancer 13
Table 5: Clinical Profile of Lapatinib 16
Table 6: Results of Randomized Clinical Trials 27
Table 7: Efficacy results in the ITT population 31
Table 8: Efficacy Results of GEST Study 34
Table 9: Response to Second-line Based on First-line VEGF-targeted Therapy Response 36
Table 10: Antitumor Activity and Biomarker Effects in Patients Treated with Linifanib for Sunitinib-Refractory Metastatic RCC 40
Table 11: Efficacy Results of Phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone alone 42
Table 12: Efficacy Results 43
Table 13: Efficacy results of PII ACT-1 trial 56
Table 14: AUC CV% and Ratio of AUCmax to AUCmin for Liposomal and Nonliposomal Anticancer Agents 74

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *